Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder caused by expanded polyglutamine repeats in the huntingtin (Htt) protein. Mutant Htt may damage and kill striatal neurons by a mechanism involving reduced production of brain-derived neurotrophic factor (BDNF) and increased oxidative and metabolic stress. Because electroconvulsive shock (ECS) can stimulate the production of BDNF and protect neurons against stress, we determined whether ECS treatment would modify the disease process and provide a therapeutic benefit in a mouse model of HD. ECS (50 mA for 0.2 s) or sham treatment was administered once weekly to male N171-82Q Htt mutant mice beginning at 2 months of age. Endpoints measured included motor function, striatal and cortical pathology, and levels of protein chaperones and BDNF. ECS treatment delayed the onset of motor symptoms and body weight loss and extended the survival of HD mice. Striatal neurodegeneration was attenuated and levels of protein chaperones (Hsp70 and Hsp40) and BDNF were elevated in striatal neurons of ECS-treated compared with sham-treated HD mice. Our findings demonstrate that ECS can increase the resistance of neurons to mutant Htt resulting in improved functional outcome and extended survival. The potential of ECS as an intervention in subjects that inherit the mutant Htt gene merits further consideration.

Modified electroconvulsive therapy for the treatment of refractory schizophrenia-like psychosis associated with Huntington’s disease

“…Recently, Mughal et al demonstrated that ECT could protect neurons against mutant huntingtin protein resulting in improved functional outcome, leading to slow disease progression [9]. In agreement with Mughal et al, the results of brain MRI and MMSE scores of before and after treatment, showed that the cognitive function of our patient remained clinically unchanged.…”

MicroRNA-613 regulates the expression of brain-derived neurotrophic factor in Alzheimer's disease

“…Previous studies have indicated that the level of BDNF was reduced in many neurodegenerative diseases, such as Huntington's disease (26), multiple sclerosis (27), and Parkinson's disease (28). In this research, we found that BDNF is also significantly decreased in the body fluid of patients and an animal model.…”

Brain-derived neurotrophic factor and its clinical implications

“…BDNF stimulates and controls growth of new neurons from neural stem cells (neurogenesis) [ 5 , 6 ], and BDNF protein and mRNA have been identified in most brain areas including the olfactory bulb, cortex, hippocampus, basal forebrain, mesencephalon, hypothalamus, brainstem and spinal cord. The levels of BDNF are decreased in many neurodegenerative diseases such as Parkinson's disease (PD) [ 7 ], multiple sclerosis (MS) [ 8 ] and Huntington's disease [ 9 ]. Besides the neuroprotective effect, BDNF plays a major role in energy homeostasis.…”